Epizyme Inc. (EPZM)

17.60
NASDAQ : Health Technology
Prev Close 17.10
Day Low/High 16.55 / 17.65
52 Wk Low/High 9.30 / 20.45
Avg Volume 465.80K
Exchange NASDAQ
Shares Outstanding 69.28M
Market Cap 1.20B
EPS -1.90
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Commit To Purchase Epizyme At $7.50, Earn 13.2% Annualized Using Options

Investors eyeing a purchase of Epizyme Inc. stock, but cautious about paying the going market price of $11.97/share, might benefit from considering selling puts among the alternative strategies at their disposal.

Epizyme Presents Preclinical Data On Novel G9a Program And Introduces Next Drug Development Candidate At The American Society Of Hematology Annual Meeting

Epizyme Presents Preclinical Data On Novel G9a Program And Introduces Next Drug Development Candidate At The American Society Of Hematology Annual Meeting

EZM8266 is the First of Three New Compounds to be Named as Part of Epizyme's Vision 2020

Epizyme Presents New Biomarker Data On Tazemetostat At The American Society Of Hematology Annual Meeting

Epizyme Presents New Biomarker Data On Tazemetostat At The American Society Of Hematology Annual Meeting

Data Highlights Company's Innovative Work in Translational Medicine to Identify Non-Hodgkin Lymphoma Patient Populations That May Derive Most Benefit

Epizyme Enters Oversold Territory (EPZM)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Epizyme Presents Data From A Phase 1 Trial Of Tazemetostat In Children With Relapsed Or Refractory INI1-Negative Solid Tumors At The 2017 AACR-NCI-EORTC International Conference On Molecular Targets And Cancer Therapeutics

Epizyme Presents Data From A Phase 1 Trial Of Tazemetostat In Children With Relapsed Or Refractory INI1-Negative Solid Tumors At The 2017 AACR-NCI-EORTC International Conference On Molecular Targets And Cancer Therapeutics

First presentation of pediatric dose escalation data in tazemetostat, showing favorable safety and tolerability with promising anti-tumor activity

First Week Of May 2018 Options Trading For Epizyme (EPZM)

First Week Of May 2018 Options Trading For Epizyme (EPZM)

Investors in Epizyme Inc. saw new options become available this week, for the May 2018 expiration.

Epizyme Announces Closing Of Public Offering Of Common Stock

Epizyme Announces Closing Of Public Offering Of Common Stock

Full Exercise of Underwriters' Option to Purchase Additional Shares

Summit Therapeutics Stock Gets Smoked After IPO Pricing

Summit Therapeutics Stock Gets Smoked After IPO Pricing

Summit Therapeutics and Epizyme are raising cash to fund new drug development.

Biotech Movers: Buzz on Potential Suitors Sends United Therapeutics Stock Soaring

Biotech Movers: Buzz on Potential Suitors Sends United Therapeutics Stock Soaring

GlaxoSmithKline could be among the suitors for United Therapeutics, the Evening Standard reported.

US Oncology Research And Epizyme Establish Collaboration To Identify Non-Hodgkin Lymphoma Patients With EZH2 Mutations

US Oncology Research And Epizyme Establish Collaboration To Identify Non-Hodgkin Lymphoma Patients With EZH2 Mutations

Eligible Patients to be Directed to Epizyme's Ongoing Phase 2 Clinical Trial of Tazemetostat in Follicular Lymphoma and Diffuse Large B-cell Lymphoma

Biotech Movers: Sangamo, Epizyme, Revance

Biotech Movers: Sangamo, Epizyme, Revance

Sangamo Therapeutics, Epizyme and Revance were among the biotech stock movers in premarket trading on June 21.

First Week of EPZM February 2018 Options Trading

Investors in Epizyme Inc. saw new options begin trading this week, for the February 2018 expiration.

Biotech Movers: AveXis, Clovis, Epizyme

Biotech Movers: AveXis, Clovis, Epizyme

AveXis, Clovis Oncology and Epizyme were among the biotech stock movers in premarket trading on June 20.

Epizyme's Positive Cancer Drug Results Likely to Catch the Eye of Celgene, J&J

Epizyme's Positive Cancer Drug Results Likely to Catch the Eye of Celgene, J&J

Epizyme sank almost 20% since their last earnings report, but recent developments show positive data from one of its keynote drugs, Tazemetostat

Alexion Pops, Biogen Falls on Executive Shuffle; Epizyme Recovers As Investors Digest Phase 2 Data

Alexion Pops, Biogen Falls on Executive Shuffle; Epizyme Recovers As Investors Digest Phase 2 Data

Epizyme, Alexion Pharmaceuticals and XBiotech were among the biotech stock movers premarket trading on June 14.

TheStreet Quant Rating: D (Sell)